A Study of Mavorixafor in Participants With Congenital and Acquired Primary Autoimmune and Idiopathic Chronic Neutropenic Disorders Who Are Experiencing Recurrent and/or Serious Infections
Trial details
- Registry ID
- NCT06056297
- Phase
- Phase 3
The FDA approved Mavorixafor (AMD11070) on 26 Apr 2024.
Drug identity checked against registry records
Also recorded as AMD11070; X4P-001
| Trial | Sponsor | Phase | Status | Primary completion |
|---|---|---|---|---|
| A Study of Mavorixafor in Participants With Congenital and Acquired Primary Autoimmune and Idiopathic Chronic Neutropenic Disorders Who Are Experiencing Recurrent and/or Serious InfectionsNCT06056297 | X4 Pharmaceuticals | Phase 3 | Recruiting | 2027-09Estimated |
| Efficacy and Safety Study of Mavorixafor in Participants With Warts, Hypogammaglobulinemia, Infections, and Myelokathexis (WHIM) SyndromeNCT03995108 | X4 Pharmaceuticals | Phase 3 | Completed | 2025-12-23Actual |
| Date as reported | Drug / company | Event | Condition | Evidence |
|---|---|---|---|---|
| 2024-04-26Day | Mavorixafor | FDA original application approvalFDA approval decision | Not specified | Open original sourceRead source excerpt{"application_number": "NDA218709", "applicant_as_listed_by_fda": "X4 PHARMS", "brand_names": ["XOLREMDI"], "active_ingredients": ["MAVORIXAFOR"], "submission_type": "ORIG", "submission_number": "1", "submission_status": "AP", "submission_status_date": "20240426", "matched_on": "drug name equals FDA sole active ingredient"} First seen: 06 Oct 2026 · Evidence last checked: 06 Oct 2026 |